BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 10407985)

  • 21. Hematopoietic colony-stimulating factors. Uses in combination with standard chemotherapeutic regimens and in support of dose intensification.
    Neidhart JA
    Cancer; 1992 Aug; 70(4 Suppl):913-20. PubMed ID: 1379115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tolerability and efficacy of GM-CSF [Leucomax] in patients with small cell lung cancer treated with intensive chemotherapy.
    Walewski J; Romejko-Jarosińska J; Zwoliński J; Falkowski S; Siedlecki P
    Med Oncol; 1996 Dec; 13(4):199-205. PubMed ID: 9152970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
    Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
    Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mobilization of peripheral blood progenitor cells following CHOP treatment combined with delayed granulocyte colony-stimulating factor administration in patients with non-Hodgkin's lymphoma.
    Takano H; Sawada K; Sato N; Natoya A; Tarumi T; Hirayama S; Koizumi K; Takahashi TA; Sekiguchi S; Koike T
    Leuk Lymphoma; 1996 May; 21(5-6):473-8. PubMed ID: 9172813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short term treatment with Escherichia coli recombinant human granulocyte-macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease.
    Aglietta M; Montemurro F; Fagioli F; Volta C; Botto B; Cantonetti M; Racanelli V; Teofili L; Ferrara R; Amadori S; Castoldi GL; Dammacco F; Levis A
    Cancer; 2000 Jan; 88(2):454-60. PubMed ID: 10640980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Optimal way of administration of granulocyte colony stimulating factor in the treatment of urological cancer].
    Okaneya T; Tsuruta T; Niwakawa M; Kawakami M; Kobayashi S; Ogawa A
    Nihon Hinyokika Gakkai Zasshi; 1993 Apr; 84(4):680-5. PubMed ID: 7684099
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral combination chemotherapy in conjunction with filgrastim (G-CSF) in the treatment of AIDS-related non-Hodgkin's lymphoma: evaluation of the role of G-CSF; quality-of-life analysis and long-term follow-up.
    Remick SC; Sedransk N; Haase RF; Blanchard CG; Ramnes CR; Nazeer T; Mastrianni DM; Dezube BJ
    Am J Hematol; 2001 Mar; 66(3):178-88. PubMed ID: 11279624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant human granulocyte colony-stimulating factor infusion and/or autologous peripheral blood stem cell transplantation as a rescue for sequential high-dose combination chemotherapy: a preliminary report.
    Chau WK; Lin CK; Chow MP; Wang SY; Liu JM; Ho CH; Chiu CF; Hsu HC; Tan TD; Chan WK
    Zhonghua Yi Xue Za Zhi (Taipei); 1994 Nov; 54(5):312-20. PubMed ID: 7530591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effective administration of recombinant granulocyte colony-stimulating factor to prevent granulocytopenia due to combination chemotherapy for testicular germ cell tumors].
    Nonomura K; Shinohara N; Shinno Y; Seki T; Koyanagi T; Nagamori S; Fujieda J; Togashi M; Ohashi N; Abe N; Toyota K; Maru A; Gotoh T; Sakakibara N; Sakashita S; Kosugi M; Adachi Y
    Hinyokika Kiyo; 1996 Sep; 42(9):699-704. PubMed ID: 8918674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short-term administration of granulocyte-macrophage colony stimulating factor decreases hematopoietic toxicity of cytostatic drugs.
    Aglietta M; Monzeglio C; Pasquino P; Carnino F; Stern AC; Gavosto F
    Cancer; 1993 Nov; 72(10):2970-3. PubMed ID: 8221563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of recombinant human granulocyte colony-stimulating factor in patients receiving chemotherapy for urogenital cancer. Urological rhG-CSF Study Group.
    Aso Y; Akaza H
    J Urol; 1992 Apr; 147(4):1060-4. PubMed ID: 1372661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
    Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
    Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized trial of sequential administration of G-CSF and GM-CSF vs. G-CSF alone following peripheral blood progenitor cell autograft in solid tumors.
    Recchia F; Accorsi P; Bonfini T; De Filippis S; Grimaldi M; Corrao G; Rosselli M; Amiconi G; Iacone A; Rea S
    J Interferon Cytokine Res; 2000 Feb; 20(2):171-7. PubMed ID: 10714552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I/II study of a stepwise dose-escalated regimen of cisplatin, etoposide and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumours.
    Bokemeyer C; Schmoll HJ; Harstrick A; Illiger HJ; Metzner B; Räth U; Hohnloser J; Clemm C; Berdel W; Siegert W
    Eur J Cancer; 1993; 29A(16):2225-31. PubMed ID: 8110490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study.
    Pujol JL; Douillard JY; Rivière A; Quoix E; Lagrange JL; Berthaud P; Bardonnet-Comte M; Polin V; Gautier V; Milleron B; Chomy F; Chomy P; Spaeth D; Le Chevalier T
    J Clin Oncol; 1997 May; 15(5):2082-9. PubMed ID: 9164221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. An NSABP pilot study in patients with metastatic or high-risk primary breast cancer. National Surgical Adjuvant Breast and Bowel Project.
    Mamounas EP; Anderson S; Wickerham DL; Clark R; Stoller R; Hamm JT; Stewart JA; Bear HD; Glass AG; Bornstein R
    Am J Clin Oncol; 1994 Oct; 17(5):374-81; discussion 382. PubMed ID: 7522393
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.
    Bunn PA; Crowley J; Kelly K; Hazuka MB; Beasley K; Upchurch C; Livingston R; Weiss GR; Hicks WJ; Gandara DR
    J Clin Oncol; 1995 Jul; 13(7):1632-41. PubMed ID: 7602352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor.
    Saxman SB; Nichols CR; Einhorn LH
    Chest; 1997 Mar; 111(3):657-60. PubMed ID: 9118704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical study of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced leukopenia].
    Shi YK; Sun Y; Su M
    Zhonghua Zhong Liu Za Zhi; 1994 Sep; 16(5):356-9. PubMed ID: 7895587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.